- 专利标题： 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors
-
申请号： US15808242申请日： 2017-11-09
-
公开(公告)号： US10428034B2公开(公告)日： 2019-10-01
- 发明人: Christopher Ryan Butler , Laura Ann McAllister , Elizabeth Mary Beck , Michael Aaron Brodney , Adam Matthew Gilbert , Christopher John Helal , Douglas Scott Johnson , Justin Ian Montgomery , Steven Victor O'Neil , Bruce Nelsen Rogers , Patrick Robert Verhoest , Damien Webb
- 申请人： PFIZER INC.
- 申请人地址： US NY New York
- 专利权人： Pfizer Inc.
- 当前专利权人： Pfizer Inc.
- 当前专利权人地址： US NY New York
- 代理商 Feng Shao
- 主分类号： C07D295/14
- IPC分类号： C07D295/14 ; C07D401/14 ; C07D401/04 ; C07D403/04 ; C07D498/10 ; C07D491/107 ; C07D401/12 ; C07D471/10 ; C07D487/04 ; C07D211/48 ; C07D471/08 ; C07D515/10 ; C07F9/6561 ; C07D405/14 ; C07D413/14 ; C07D405/12 ; C07D493/10
摘要：
The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
公开/授权文献
信息查询
